BiopharmaTrend.com

A fresh viewpoint on drug discovery, pharma, and biotech

Subscribe | Become an author | Author LogIn

Website

Contact us at info@biopharmatrend.com to request profile updates/corrections. You must be an official company representative to do so (only requests from corporate emails are accepted).

Exscientia

About

At the forefront of small molecule drug discovery

We are the first company to automate drug design, surpassing conventional human endeavour.

Our AI driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters.

With better information to hand than any researcher could acquire individually, our knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, ADME and other key criteria. From this, a selection of the best, information-rich compounds are selected for synthesis and assay.

With new experimental data generated, the results are integrated and the next design cycle initiated. Rapid design-make-test cycles ensure unparalleled progress towards desired project goals.

Exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.

Year Founded
2012
Geography
United Kingdom based
Funding
$15.0 M
Field/area focus
Chemistry and Biology
Research papers
1
Therapeutic focus
  • Metabolics
  • Oncology
  • Neuroscience
Data type
  • chemical notations
  • high-content screening
  • SAR
Research Use Case
  • Lead Identification
  • Preclinical Experiments
  • Drug Repurposing
Product type
  • small molecules
Business model
  • contract research

Industry Partnerships

YearPartnerFocus
2013Janssen
2014Sunovion Pharmaceuticalsdrug discovery and optimization of new drugs for mental illnesses (by analyzing data obtained with phenotype drug discovery)
2015Sumitomo DainipponDeveloped a (lead candidate) bispecific, dual-agonist compound that selectively activates two GPCR families
2016Evotecdiscover and develop first-in-class bispecific small molecule immuno-oncology therapies. The initial focus is cancer-related adenosine targets
2017Sanofidiscover bispecific small-molecule drugs against metabolic diseases. (from excientia: comp. design, target identification)
2017GSKuse artificial intelligence to discover new small molecule therapies for up to 10 disease-related targets.

Posts Mentioning This Company

How Big Pharma Adopts AI To Boost Drug Discovery - Oct. 8, 2018
Biopharma Insights